The Federal Circuit raised the bar a few notches on patent claims for methods of using drugs in combination, especially if one of the drugs is used in other combination therapies. Read More
Scientifically speaking, big data projects are the order of the day. With increasing technological abilities – in computing power, but also in methods to visualize and map biological phenomena – such projects strive for comprehensiveness, most often indicated by an "ome" attached to their field of study: the genome, the transcriptome, the human microbiome. Read More
Cardio3 Biosciences SA is the third European biotechnology company to dip its toes in the initial public offering (IPO) waters this year. The Belgian stem cell therapy developer is seeking up to €24.7 million (US$32.5 million) in an offering on the NYSE Euronext Exchanges in Brussels and Paris. Read More
Plowing ahead with the second Phase III trial to evaluate Androxal (enclomiphene), the estrogen receptor antagonist for secondary hypogonadism, Repros Therapeutics Inc. priced an underwritten public offering of about 3.7 million shares at $19 each, grossing about $71.2 million. Read More
• Medicago Inc., of Quebec City, said it successfully produced a rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using its plant-based manufacturing system. That achievement completes the first part of the firm's collaboration with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, toward the development of a rotavirus vaccine candidate. Read More
• Pharmacyclics Inc., of Sunnyvale, Calif., said the New England Journal of Medicine online published results of a Phase II study evaluating the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, in patients with relapsed/refractory mantle cell lymphoma (MCL). The data suggest ibrutinib may be effective and generally well tolerated in patients with relapsed/refractory MCL. Read More
• H. Lundbeck A/S, of Copenhagen, Denmark, said it plans to further optimize its commercial structure, dividing its commercial operations into six regions: Europe, the U.S., Canada, Asia, Latin America and the Middle East & Global Distribution. It also plans to simplify the commercial structure in Europe by organizing its more than 30 affiliates in 10 business units. The initiative follows Lundbeck's establishment of a more flexible commercial organization in Europe last year. Read More
